Total Revenue

-26% (from $2.520M to $1.864M)

Total Revenue declined by 26% YoY, likely driven by lower sales volume or shifts in product mix compared to Q1 2024, although specific underlying business factors are not detailed in the documents. " "

Net Loss

-72% (from $29.958M to $8.364M)

Net Loss narrowed by 72% YoY, reflecting a significant improvement possibly due to strong cost-control measures and reductions in non-recurring expenses that were present in Q1 2024. " "

R&D Expense

-85% (from $14.222M to $2.116M)

R&D Expense dropped by 85% YoY as a result of strategic changes—particularly the discontinuation of the istisociclib clinical trial and reduction in personnel-related costs following restructuring—mirroring actions seen in previous periods where R&D activities were reined in. " "

Operating Loss

-70% (from $31.994M to $9.442M)

Operating Loss improved by 70% YoY, largely driven by the steep declines in R&D and other operating expenses, indicating that the cost reductions executed in Q1 2025 built upon moves taken in prior periods. " "

Operating Cash Flow

46% improvement (from $(23.899)M to $(12.842)M)

Operating Cash Flow improved with a 46% reduction in outflows, suggesting better management of operational activities and working capital compared to Q1 2024, which supported enhanced cash usage efficiencies despite persistent cash use in operations. " "

Liquidity

+8% increase (from $84.571M to $91.577M)

Liquidity strengthened by an 8% increase in cash and cash equivalents, improving from Q4 2024 to Q1 2025, potentially due to effective cash management and sourcing strategies that built on the previous period's lower liquidity levels. " "

Total Assets

-13% (from $124.363M to $108.140M)

Total Assets declined by 13% YoY, with the reduction driven predominantly by significant withdrawals in short-term investments and decreases in property and equipment, reflecting a broader contraction of the asset base relative to the previous period. " "

Total Liabilities

-23% (from $36.783M to $28.328M)

Total Liabilities fell by 23% YoY, due primarily to reductions in current liabilities—such as lower accounts payable, decreased accrued expenses, and the removal of the current portion of deferred revenue—which denotes a healthier liability structure compared to Q1 2024. " "